CER: Pathway to Personalized Medicine
A data-driven approach to clinical decision-making improves the quality of healthcare. Significantly, analytical tools for cost-benefit evaluation of medicines, procedures and services eliminate unwarranted spending.
At Healthdatamanagement.com, Infosys' expert blogs on Comparative Effectiveness Research (CER) as a clinical pathway management tool for personalized medicine.
Join the discussion
ObamaCare's Comparative Effectiveness Research
Data on the comparative effectiveness of treatment options avoids ineffective and expensive alternatives.
CER: Much More than a P4P Tool
All stakeholders benefit from an optimized pathway, including payor and provider organizations, pharmaceutical companies and device manufacturers.
Published with permission of Health Data Management
Learn more about Infosys' offerings for healthcare